BEXAROTENE AUGMENTATION SUPPORTS THE RETINOID DYSREGULATION HYPOTHESIS OF SCHIZOPHRENIA: FINDINGS FROM A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL

被引：0

作者：

Lerner, Vladimir ^{[1
]}

Miodownik, Chanoch ^{[1
]}

Sirota, Pinchas ^{[2
]}

Gibel, Anatoly ^{[3
]}

Bush, Ilan ^{[1
]}

Hadi, Elliot ^{[2
]}

Benatov, Ruben ^{[2
]}

Ritsner, Michael S. ^{[3
]}

机构：

[1] Ben Gurion Univ Negev, Fac Hlth Sci, Div Psychiat, Minist Hlth,Mental Hlth Ctr, Beer Sheva, Israel

[2] Abarbanel Mental Hlth Ctr, Bat Yam, Israel

[3] Shaar Menashe Mental Hlth Ctr, Hadera, Israel

来源：

ISRAEL JOURNAL OF PSYCHIATRY AND RELATED SCIENCES | 2012年 / 49卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

引用

页码：36 / 36

页数：1

共 50 条

[21] EFFECT OF 6-WEEK TREATMENT WITH TOPICAL CORTICOSTEROID IN PATIENTS WITH SYMPTOMATIC HAND OSTEOARTHRITIS: A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Wang, Y.
Estee, M.
Gan, D.
Lim, Y.
Heritier, S.
Wluka, A.
Hussain, S.
Trevaskis, N.
Cicuttini, F.
OSTEOARTHRITIS AND CARTILAGE, 2023, 31 : S66 - S67
[22] Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial
Lin, C-H
Chen, P-K
Wang, S-H
Lane, H-Y
JOURNAL OF PSYCHOPHARMACOLOGY, 2019, 33 (08) : 1030 - 1033
[23] Tetrabenazine Augmentation in Treatment-Resistant Schizophrenia A 12-Week, Double-Blind, Placebo-Controlled Trial
Remington, Gary
Kapur, Shitij
Foussias, George
Agid, Ofer
Mann, Steve
Borlido, Carol
Richards, Sandy
Javaid, Naima
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (01) : 95 - 99
[24] Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study
Toshihiko Kinoshita
Ya-Mei Bai
Jong-Hoon Kim
Mutsuo Miyake
Nobuyuki Oshima
Psychopharmacology, 2016, 233 : 2663 - 2674
[25] Efficacy and Safety of Ulotaront in the Treatment of Schizophrenia: Results of Two 6-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials
Kane, John
Dworak, Heather
Koblan, Kenneth
Szegedi, Armin
Goldman, Robert
Li, Yan
Fitzgerald, Alison
Loebel, Antony
Marder, Stephen
NEUROPSYCHOPHARMACOLOGY, 2023, 48 : 351 - 351
[26] Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study
Kinoshita, Toshihiko
Bai, Ya-Mei
Kim, Jong-Hoon
Miyake, Mutsuo
Oshima, Nobuyuki
PSYCHOPHARMACOLOGY, 2016, 233 (14) : 2663 - 2674
[27] Efficacy and safety of lurasidone in schizophrenia: pooled analysis of European results from double-blind, placebo-controlled 6-week studies
Calisti, Fabrizio
Cattaneo, Agnese
Calabrese, Mariangela
Mao, Yongcai
Tocco, Michael
Pikalov, Andrei
Goldman, Robert
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2022, 37 (05) : 215 - 222
[28] Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial
Chang, Jae Seung
Ahn, Yong Min
Park, Hye Jean
Lee, Kyu Young
Kim, Se Hyun
Kang, Ung Gu
Kim, Yong Sik
JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (05) : 720 - 731
[29] Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia
Ferenc Martenyi
Nikolay N. Zavadenko
Natalia B. Jarkova
Alexandr A. Yarosh
Victoria O. Soldatenkova
Leonid M. Bardenstein
Irina A. Kozlova
Nikolay G. Neznanov
Olga I. Maslova
Andrey S. Petrukhin
Nina K. Sukchotina
Valeriy P. Zykov
European Child & Adolescent Psychiatry, 2010, 19 : 57 - 66
[30] Effect of 6-week treatment with topical betamethasone dipropionate in patients with symptomatic hand osteoarthritis: A randomized double-blind, placebo-controlled trial
Wang, Yuanyuan
Estee, Mahnuma Mahfuz
Gan, Desmond
Lim, Yuan Z.
Heritier, Stephane
Wluka, Anita E.
Hussain, Sultana Monira
Trevaskis, Natalie L.
Cicuttini, Flavia M.
OSTEOARTHRITIS AND CARTILAGE OPEN, 2023, 5 (03):

← 1 2 3 4 5 →